###begin article-title 0
CCL5 regulation of mucosal chlamydial immunity and infection
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 239 248 239 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 717 726 717 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 424 427 <span type="species:ncbi:9606">man</span>
Following genital chlamydial infection, an early T helper type 1 (Th1)-associated immune response precedes the activation and recruitment of specific Th1 cells bearing distinct chemokine receptors, subsequently leading to the clearance of Chlamydia. We have shown that CCR5, a receptor for CCL5, is crucial for protective chlamydial immunity. Our laboratory and others have also demonstrated that CCL5 deficiencies found in man and animals can increase the susceptibility and progression of infectious diseases by modulating mucosal immunity. These findings suggest the CCR5-CCL5 axis is necessary for optimal chlamydial immunity. We hypothesized CCL5 is required for protective humoral and cellular immunity against Chlamydia.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 135 155 135 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia muriduram </italic>
###xml 407 409 407 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
The present study revealed that CCR5 and CCL5 mRNAs are elevated in the spleen, iliac lymph nodes (ILNs), and genital mucosa following Chlamydia muriduram challenge. Antibody (Ab)-mediated inhibition of CCL5 during genital chlamydial infection suppressed humoral and Th1 > Th2 cellular responses by splenic-, ILN-, and genital mucosa-derived lymphocytes. Antigen (Ag)-specific proliferative responses of CD4+ T cells from spleen, ILNs, and genital organs also declined after CCL5 inhibition.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 72 84 72 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muriduram</italic>
The suppression of these responses correlated with delayed clearance of C. muriduram, which indicate chlamydial immunity is mediated by Th1 immune responses driven in part by CCL5. Taken together with other studies, the data show that CCL5 mediates the temporal recruitment and activation of leukocytes to mitigate chlamydial infection through enhancing adaptive mucosal humoral and cellular immunity.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis </italic>
###xml 348 349 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 350 351 350 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 623 624 623 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 625 626 625 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 627 628 627 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 836 837 836 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 838 839 838 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 942 951 942 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 0 21 <span type="species:ncbi:813">Chlamydia trachomatis</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen in the United States; infection results in devastating sequelae, including pelvic inflammatory disease and infertility. Animal models and clinical studies of infected patients have indicated that protective chlamydial immunity is primarily mediated by Th1 responses [1-3]. The induction of such immunity involves rapid recruitment and activation of certain effector immune cells, specifically Th1 cells and dendritic cells (DCs) into the local genital mucosa to clear the infection, arrest ascending disease, and prevent major complications [1,4-7]. In addition, certain complimentary B cell functions - principally Ab-mediated enhancement of Ag presentation - lead to activation of Ag-specific Th1 cells dependent in part by Fc-receptor-mediated events [1,8]. Thus, both cell-mediated and humoral immune responses are required for long-term protection against Chlamydia.
###end p 9
###begin p 10
###xml 43 53 43 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 595 597 595 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 741 743 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
With the major elements of protective anti-Chlamydia immunity defined, a number of candidate vaccines have been described [1]. Chemokines have emerged as important factors and possible mucosal adjuvants that function in lymphocyte activation and recruitment [9-11]. Indeed, a qualitative relationship exists between the class of chemokines secreted following infection, the type of immune response (cellular or humoral immunity) elicited, and the fate of the host following infection [12-15]. The profile of chemokine expression serves as a reliable indicator of immune response type (i.e., Th1 vs. Th2). In this respect, the CCL5-CCR5 axis has been demonstrated to be preferentially involved in the activation and function of Thl cells [10,16,17].
###end p 10
###begin p 11
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 596 608 596 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ccr5&#916;32 </italic>
###xml 644 646 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 847 857 843 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 858 860 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 957 966 953 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 1152 1162 1148 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 1360 1369 1356 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 393 398 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
###xml 1196 1201 <span type="species:ncbi:10090">mouse</span>
CCL5 is secreted by epithelial cells, macrophages, fibroblasts, platelets, and activated T cells [18]. This CC chemokine is known to regulate T cell differentiation and polarize Th1 >> Th2 subtypes [10,13,18,19] as well as numerous physiological functions of leukocytes including migration. Polymorphisms in CCR5 and CCL5 modulate immune responses as well as susceptibility and progression to HIV-1 and AIDS, respectively [20,21]. We also showed that many of the deleterious complications of genital chlamydial infection, due to Th1-mediated inflammation, are not present in individuals with the ccr5Delta32 mutation or in CCR5-deficient mice [22]. CCR5 expression following genital chlamydial infection is followed by an early Th1-like response that precedes activation and mucosal recruitment of Ag-specific Th1 cells necessary for clearance of Chlamydia [23]. These findings indicate that CCL5 might be important for inducing protective immunity against Chlamydia. However, it is not certain what affect CCL5 deficiency would have on chlamydial disease. We tested the hypothesis that CCL5 is essential for inducing adaptive mucosal immunity against Chlamydia by Ab inhibition using a reliable mouse model of genital chlamydial infection. Results revealed CCL5 supports the induction of Th1 cytokine and immunoglobulin IgG2a as well as IgA responses against Chlamydia.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Expression of chemokines after genital Chlamydia infection
###end title 13
###begin p 14
###xml 298 299 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
CCL5, CCR5, and IFN-gamma mRNAs were measured by quantitative RT-PCR analysis after genital chlamydial infection. A significant increase in CCR5, CCL5, and IFNgamma gene expression in the spleen and ILN was observed 7 days after genital infection when compared with levels before infection (Figure 1). These mRNA levels modestly declined at inductive sites 14 days after infection. CCR5, but not CCL5 or IFN-gamma mRNA expression by fallopian tube-, uterus-, and cervix- derived lymphocytes were considerably higher than levels before infection. Indeed, CCR5 mRNA expression by fallopian tube lymphocytes was significantly higher 7 and 14 days post infection. These data suggest that increases in CCL5, CCR5, and IFN-gamma mRNA expression during early stages of infection at inductive sites (i.e., spleen and ILN) preceded CCR5 expression at effectors sites (i.e., fallopian tube(s), uterus, and cervix). The pattern of CCL5 and CCR5 as well as IFN-gamma illustrates how this chemokine axis coincides with both the innate (recognition phase, 0 to 7 days) and adaptive (activation, effector, and decline/homeostasis phases) immune responses to this pathogen and associated inflammation.
###end p 14
###begin p 15
###xml 49 59 45 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 0 69 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CCL5, CCR5, and IFN-&#947; mRNA expression during <italic>Chlamydia </italic>infections</bold>
###xml 116 129 112 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 431 434 423 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10 </sub>
###xml 632 634 622 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 116 128 <span type="species:ncbi:83560">C. muridarum</span>
###xml 249 254 <span type="species:ncbi:10090">mouse</span>
###xml 568 572 <span type="species:ncbi:10090">mice</span>
###xml 669 673 <span type="species:ncbi:10090">mice</span>
CCL5, CCR5, and IFN-gamma mRNA expression during Chlamydia infections. Groups of female BALB/c mice challenged with C. muridarum and total RNA was isolated from lymphocytes isolated from the spleen, ILNs, fallopian tubes, uterus, and cervix of each mouse, under sterile conditions before or 7 and 14, 21 and 42 days after challenge. The levels of CCL5, CCR5 and IFN-gamma mRNA expression were ascertained after RT-PCR analysis. Log10 copies of transcripts were expressed relative to the actual copies of 18S rRNA +/- SEM. Experiments were repeated 3 times to yield 15 mice per group. Asterisks (*) indicate significant differences (p < 0.01) between tissues from naive mice.
###end p 15
###begin title 16
###xml 27 40 27 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 27 39 <span type="species:ncbi:83560">C. muridarum</span>
Proliferative responses of C. muridarum genital infection modulated by CCL5 inhibition
###end title 16
###begin p 17
###xml 22 34 22 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum</italic>
###xml 185 187 185 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 259 271 259 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum</italic>
###xml 416 428 416 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum</italic>
###xml 476 477 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 588 590 588 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 636 649 636 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 735 744 735 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 757 759 757 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 22 34 <span type="species:ncbi:83560">C. muridarum</span>
###xml 259 271 <span type="species:ncbi:83560">C. muridarum</span>
###xml 304 308 <span type="species:ncbi:10090">mice</span>
###xml 416 428 <span type="species:ncbi:83560">C. muridarum</span>
###xml 463 467 <span type="species:ncbi:10090">mice</span>
###xml 636 648 <span type="species:ncbi:83560">C. muridarum</span>
We next characterized C. muridarum-specific proliferative responses of T helper cells isolated from the spleen, ILNs, fallopian tube(s), uterus, and cervix, 42 days after challenge. CD4+ T cells isolated from these mucosal and systemic immune compartments of C. muridarum-infected and control Ab-treated mice exhibited marked increases in Ag-specific proliferative responses compared to disease-free (uninfected) or C. muridarum-infected and anti-CCL5 Ab-treated mice (Figure 2). Notably, systemic and mucosal inductive sites of the spleen and ILN, respectively, contained Ag-specific CD4+ T cells that significantly proliferated after C. muridarum re-stimulation. These results suggest that CCL5 is required for optimal generation of Chlamydia-specific CD4+ T cells that proliferate after Ag recognition.
###end p 17
###begin p 18
###xml 22 24 22 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 44 0 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia-specific CD4<sup>+ </sup>T cell proliferation</bold>
###xml 100 113 100 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 296 298 295 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 355 357 354 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 373 375 372 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 455 457 450 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 535 539 530 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450 </sub>
###xml 716 718 709 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 100 112 <span type="species:ncbi:83560">C. muridarum</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
###xml 764 768 <span type="species:ncbi:10090">mice</span>
###xml 773 777 <span type="species:ncbi:10090">mice</span>
Chlamydia-specific CD4+ T cell proliferation. Groups of naive or female BALB/c mice challenged with C. muridarum and received 100 mul of control Ab or anti-CCL5 Ab solution every 3 days. Following sacrifice 42 days after challenge, spleen-, ILN-, fallopian tubes-, uterus-, and cervix-derived CD4+ T cells were purified and cultured at a density of 5 x 106 cells/ml with 106 cells/ml of gamma-irradiated feeder splenocytes for 3 days. Proliferation of CD4+ T cells was measured by BrdU incorporation. The data presented are the mean OD450 for proliferative +/- SEM of quadruplicate cultures. Experiments were repeated 3 times to yield 15 mice per group. Asterisks (*) indicate statistically significant differences (p < 0.01) between untreated, control Ab-treated mice and mice treated with anti-CCL5 Ab.
###end p 18
###begin title 19
CCL5 modulation of Chlamydia-specific humoral responses
###end title 19
###begin p 20
###xml 91 100 91 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 293 302 293 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 454 455 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 556 568 556 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum</italic>
###xml 715 728 715 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 805 814 805 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 222 226 <span type="species:ncbi:10090">mice</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 441 445 <span type="species:ncbi:10090">mice</span>
###xml 556 568 <span type="species:ncbi:83560">C. muridarum</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
###xml 715 727 <span type="species:ncbi:83560">C. muridarum</span>
To test the role of CCL5 in Th1-biased humoral responses to genital infection, we measured Chlamydia-specific IgG1, IgG2a, IgG2b, IgG3 and IgM Abs in sera as well as Ag-specific IgA and IgG Abs in vaginal washes. Infected mice that received control Ab displayed significantly higher levels of Chlamydia-specific serum IgG2a, followed by IgG2b responses than compared to similar mice that received anti-CCL5 Ab or mock-infected (i.e., naive) mice (Figure 3). Analysis of vaginal secretions revealed a significant increase in Ag-specific IgA Ab responses in C. muridarum-challenged mice that received control Ab when compared with similar mice that received anti-CCL5 Ab or uninfected animals. These results indicate C. muridarum infection enhanced Th1-biased humoral responses and CCL5 blockade attenuated Chlamydia-specific IgG2a serum responses as well as vaginal IgA responses.
###end p 20
###begin p 21
###xml 61 70 61 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 0 70 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Serum and vaginal Ab responses of mice infected with genital <italic>Chlamydia</italic></bold>
###xml 126 139 126 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 258 267 257 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 677 679 674 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 126 138 <span type="species:ncbi:83560">C. muridarum</span>
###xml 311 315 <span type="species:ncbi:10090">mice</span>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
###xml 745 749 <span type="species:ncbi:10090">mice</span>
Serum and vaginal Ab responses of mice infected with genital Chlamydia. Groups of naive or female BALB/c mice challenged with C. muridarum and received 100 mul of control Ab or anti-CCL5 Ab solution every 3 days. Following sacrifice 42 days after challenge, Chlamydia-specific serum and vaginal Ab responses of mice were determined by ELISA that was capable of detecting > 20 pg/ml of IgM, IgG, IgA, and IgG subclass Abs. The data presented are the mean concentration of IgG1, IgG2a, IgG2b, IgG3, IgM, IgG, or IgA +/- SEM of three separate experiments. Experiments were repeated 3 times to yield 15 mice per group. Asterisks (*) indicate statistically significant differences (p < 0.01) between untreated and control Ab- or anti-CCL5 Ab-treated mice.
###end p 21
###begin title 22
###xml 32 45 32 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 32 44 <span type="species:ncbi:83560">C. muridarum</span>
T helper cytokine responses and C. muridarum shedding
###end title 22
###begin p 23
###xml 8 18 8 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 84 86 84 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 258 260 258 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 502 504 498 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 517 529 513 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum</italic>
###xml 742 744 738 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 834 847 830 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 903 916 899 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 1038 1040 1034 1036 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1154 1156 1150 1152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1241 1254 1237 1250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 1295 1305 1291 1301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia-</italic>
###xml 1317 1319 1313 1315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1630 1631 1626 1627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
###xml 382 386 <span type="species:ncbi:10090">mice</span>
###xml 428 432 <span type="species:ncbi:10090">mice</span>
###xml 517 529 <span type="species:ncbi:83560">C. muridarum</span>
###xml 629 633 <span type="species:ncbi:10090">mice</span>
###xml 707 711 <span type="species:ncbi:10090">mice</span>
###xml 834 846 <span type="species:ncbi:83560">C. muridarum</span>
###xml 884 888 <span type="species:ncbi:10090">mice</span>
###xml 903 915 <span type="species:ncbi:83560">C. muridarum</span>
###xml 1061 1065 <span type="species:ncbi:10090">mice</span>
###xml 1241 1253 <span type="species:ncbi:83560">C. muridarum</span>
###xml 1478 1490 <span type="species:ncbi:83560">C. muridarum</span>
###xml 1554 1558 <span type="species:ncbi:10090">mice</span>
###xml 1617 1621 <span type="species:ncbi:10090">mice</span>
###xml 1647 1651 <span type="species:ncbi:10090">mice</span>
Genital Chlamydia infection up-regulated Ab responses as well as splenic and ILN CD4+ T cell proliferative responses. We next examined whether these effects were mediated in part through T helper cytokine responses. IL-2 secreted by Ag-stimulated splenic CD4+ T cells from infected mice that received control Ab was significantly higher than levels from cells isolated from similar mice that received anti-CCL5 Ab or uninfected mice (Figure 4). The secretion of IFN-gamma from splenic, but not ILN, CD4+ T cells from C. muridarum-infected and control Ab-treated were considerably higher than T helper cells isolated from similar mice treated with anti-CCL5 Ab or uninfected animals. Chlamydial infection of mice lead to the development of CD4+ T cells that significantly secreted IL-6, IL-10, and GM-CSF, but not IL-4, in response to C. muridarum re-stimulation. Anti-CCL5 Ab-treated mice infected with C. muridarum resulted in T helper cells with reduced IL-6, IL-10, and GM-CSF secretion following Ag re-stimulation when compared to CD4+ T cells from similar mice treated with control Ab; however, the secretion pattern of Th2 cytokine responses by CD4+ T cells isolated from ILNs did not significantly change. These results indicate that C. muridarum infection invoked splenic, but not ILNs, Chlamydia-specific CD4+ T cells that secreted Th1 cytokines as well as IL-6, IL-10, and GM-CSF, which were reduced by CCL5 blockade. The extent of chlamydial infection, determined by C. muridarum detected in cervico-vaginal swabs, was significantly higher in mice receiving anti-CCL5 Ab treatment than compared to control mice (Figure 5). However, all mice resolved chlamydial infection in < 90 days.
###end p 23
###begin p 24
###xml 34 36 34 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 49 58 49 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 0 72 0 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink">T helper cytokine secretion by CD4<sup>+ </sup>T cells from <italic>Chlamydia</italic>-infected mice</bold>
###xml 128 141 128 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 287 289 286 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 362 364 361 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 380 382 379 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 744 746 733 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 128 140 <span type="species:ncbi:83560">C. muridarum</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
###xml 812 816 <span type="species:ncbi:10090">mice</span>
T helper cytokine secretion by CD4+ T cells from Chlamydia-infected mice. Groups of naive or female BALB/c mice challenged with C. muridarum and received 100 mul of control Ab or anti-CCL5 Ab solution every 3 days. Following sacrifice 42 days after challenge, spleen- and ILN-derived CD4+ T cells from these mice were purified and cultured at a density of 5 x 106 cells/ml with 106 cells/ml of gamma-irradiated feeder splenocytes for 3 days. Cytokines present in cultured supernatants were determined by ELISA that was capable of detecting < 10 pg of IL-2, IFN-gamma, IL-4, IL-6, IL-10, or GM-CSF. The data presented are the mean cytokine (pg/ml) +/- SEM of quadruplicate cultures. Asterisks (*) indicate statistically significant differences (p < 0.01) between untreated and control Ab- or anti-CCL5 Ab-treated mice.
###end p 24
###begin p 25
###xml 11 20 11 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 0 29 0 29 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Changes in <italic>Chlamydia</italic>-shedding</bold>
###xml 95 107 95 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum</italic>
###xml 279 289 279 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 442 452 442 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 557 568 557 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydiae </italic>
###xml 727 729 727 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 31 35 <span type="species:ncbi:10090">Mice</span>
###xml 95 107 <span type="species:ncbi:83560">C. muridarum</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 649 653 <span type="species:ncbi:10090">mice</span>
###xml 795 799 <span type="species:ncbi:10090">mice</span>
Changes in Chlamydia-shedding. Mice treated with control Ab or anti-CCL5 Ab were infected with C. muridarum. The status of infection was monitored for live organism shedding by culturing periodic cervico-vaginal swabs from individual mice every week for 42 days after challenge. Chlamydia present in swabs were detected by infecting McCoy cells with vaginal swab rinses and staining infected monolayer with FITC-labeled, genus-specific, anti-Chlamydia Abs to count inclusion bodies (> 10 IFUs/ml) by direct immuno-fluorescence. BD indicates the presence of Chlamydiae was below this level of detection. Experiments were repeated 3 times to yield 15 mice per group. Asterisks (*) indicate statistically significant differences (p < 0.01) between untreated and control Ab- or anti-CCL5 Ab-treated mice.
###end p 25
###begin title 26
Discussion
###end title 26
###begin p 27
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 437 450 433 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 609 619 601 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 700 702 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 784 794 772 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 868 878 856 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 1177 1179 1161 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 437 449 <span type="species:ncbi:83560">C. muridarum</span>
Th1-mediated immune responses are essential to control the chlamydial infection [22]. It has been shown in previous studies that CCL3, CCL4 and CCL5 enhance adaptive immunity through Th1 cytokine and co-stimulatory molecule modulation [10,11,15,16]. In this study, we demonstrate some of the cellular and molecular mechanisms of CCL5-mediated chlamydial immunity. Importantly, IFN-gamma mRNA was not significantly elevated 14 days after C. muridarum infection. IL-12p40 mRNA expression coincided with CCL5, but typically preceded IFN-gamma mRNA expression (data not shown). Indeed, early genital clearance of Chlamydia has been shown to occur in an IL-12-dependent and IFN-gamma-independent fashion [24]; so, further studies will be required to dissect the roles of IL-12 and CCL5 in Chlamydia clearance and immunity. The present study shows that 7 days after genital Chlamydia infection, CCL5, CCR5, and IFNgamma mRNA levels were elevated in inductive sites, while CCR5 mRNA expression was higher in the fallopian tubes than in the uterus and cervix. To this end, similar yet differential chemokine expression patterns have been reported within anatomically distinct regions [25].
###end p 27
###begin p 28
###xml 3 5 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 133 148 133 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. trachomatis </italic>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 360 362 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 363 365 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 591 594 583 586 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&gt;&gt; </bold>
###xml 133 147 <span type="species:ncbi:813">C. trachomatis</span>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
CD4+ Th1 cells (and associated cytokines, chemokines, etc.) are critical elements in the immune response, stimulated by an ascending C. trachomatis infection in the female genital tract [26]. Indeed, studies of chlamydial infection in knockout mice support the importance of class II MHC, CD4, IL-12, IFN-gamma, and IFN-gamma receptor for chlamydial immunity [27-30]. Our data suggest that CCL5 interactions are comparably important and mediate the temporal recruitment and activation of T cells to mitigate chlamydial infection through protective mucosal adaptive immunity by enhancing Th1 >> Th2 humoral and cellular immune responses.
###end p 28
###begin p 29
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 554 556 550 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 731 744 727 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muriduram </italic>
###xml 834 836 830 832 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 845 847 841 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 918 920 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1056 1081 1052 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Streptococcus pneumoniae </italic>
###xml 1056 1080 <span type="species:ncbi:1313">Streptococcus pneumoniae</span>
###xml 1084 1088 <span type="species:ncbi:10090">mice</span>
CCL3 and CCL4 are also CCR5 ligands, but these chemokines were not remarkably elevated compared to CCL5, which was the most abundant CCR5 ligand expressed during the early stages (i.e., < 7 days) of chlamydial infection. CCL5 is an important factor in the homing of lymphocytes that express CCR5, CCR4, CCR3 and CCR1 [31-33]. It was also demonstrated from our earlier studies that CCL5 can increase the proliferation and activation of Ag stimulated T lymphocytes [10]. These findings coincide with marked increases in CCL5 and IFN-gamma production by CD4+ T cells during chlamydial infection. It is also plausible that CCL5 blockade might reduce the ability of innate immune cells (e.g., NK cells, macrophages, etc.) to respond to C. muriduram challenge. Previously, we demonstrated that CCL5 inhibition decreased the numbers of NK1.1+ and CD11b+ leukocytes at mucosal effector sites following pneumococcal challenge [34]. However, T cells were the primary lymphocyte-subtype that were reduced following CCL5 blockade during the hyper cellular response to Streptococcus pneumoniae in mice.
###end p 29
###begin p 30
###xml 8 18 8 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 143 145 143 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 292 307 292 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. trachomatis </italic>
###xml 354 364 354 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 393 395 393 395 <bold xmlns:xlink="http://www.w3.org/1999/xlink">. </bold>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 587 597 587 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 766 775 766 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 256 261 <span type="species:ncbi:9606">women</span>
###xml 292 306 <span type="species:ncbi:813">C. trachomatis</span>
Genital Chlamydia infection of mice enhanced Ag-specific Abs in serum and vaginal secretions as well as proliferative cytokine responses by CD4+ T cells isolated from systemic and mucosal compartments. High levels of IgA in cervical secretions in infected women correlate with low numbers of C. trachomatis shedding and B cells are required to eliminate Chlamydia in a secondary infection [35]. We have previously shown that CCL5 induces Ag-specific titers of IgG2a, followed by IgG2b, IgG3, and IgG1 [10], CCL3 and CCL4 enhance Ag-specific IgG1 and IgG2b responses [11]. In this study, Chlamydia infection enhanced IgG2a Ab responses, which were reduced after CCL5 inhibition. This highlights the importance of this chemokine in Th1-associated Ab responses against Chlamydia.
###end p 30
###begin p 31
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 324 334 324 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia-</italic>
###xml 542 551 542 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 585 598 585 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 585 597 <span type="species:ncbi:83560">C. muridarum</span>
The precise cytokine signals required for S-IgA production are not completely understood and studies show both Th1-and Th2-type cell-derived cytokines are important for S-IgA production [36-38]. We have previously shown that chemokines like XCL1 and CCL5 induce IgA production [9,10]. The sharp IgA Ab response generated by Chlamydia-infected mice also correlated with the predominant Th1 >> Th2 cytokine response induced by this infection, which were reduced by CCL5 blockade. These results suggest that CCL5 is required in part for optimal Chlamydia-specific IgA Ab responses during C. muridarum infection.
###end p 31
###begin p 32
###xml 64 77 64 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 269 278 269 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 383 392 383 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 483 496 483 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 691 692 691 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 64 76 <span type="species:ncbi:83560">C. muridarum</span>
###xml 483 495 <span type="species:ncbi:83560">C. muridarum</span>
Mucosal, but not serum, IgA Abs were selectively elevated after C. muridarum challenge, presumbably due to the compartmentalized common mucosal immunity system. In particular, IgA Ab-secreting cells predominantly populate the lamina propria of the mucosa. In contrast, Chlamydia-specific IgG Abs were not detected in vaginal secretions. This confirms other studies that show vaginal Chlamydia-specific IgG Abs are not present at high levels (relative to IgA) in vaginal washes after C. muridarum challenge [39,40]. However, intranasal, subcutaneous or transcutaneous immunization using mucosal adjuvants can induce vaginal wash Ag-specific IgG Ab titers that are comparable to those of IgA [9,41-45].
###end p 32
###begin p 33
###xml 64 66 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 127 137 123 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 188 198 184 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 428 430 424 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 482 492 478 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 646 658 642 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum</italic>
###xml 671 673 667 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 646 658 <span type="species:ncbi:83560">C. muridarum</span>
IFN-gamma production is often associated with IgG2a production [46] and may account for the systemic humoral responses against Chlamydia following vaginal challenge. In the present study, Chlamydia infection induced a profound IgG2a Ab response compared to other IgG subclass Abs. The analysis of mucosal and systemic responses revealed a bias toward Th1 >> Th2 type of responses. While little is known regarding Ag-specific CD4+ T cell (IL-4 and GM-CSF) secretory responses during Chlamydia infection, we show that these T helper cytokines were increased during chlamydial infection. CCL5 blockade diminished these cellular responses along with C. muridarum-specific CD4+ T cell secretion of IFN-gamma and IL-2.
###end p 33
###begin p 34
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 612 621 612 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
Contradictory studies demonstrated the ability of CCL5 to promote both Th1-and Th2-type responses. It was reported that anti-CCL5 Ab treatment in mice decreased mycobacterial-inducible Th2-type lesions while increasing schistosomal-inducible Th2-type granulomas [47]. However, studies from our laboratory suggest CCL5 enhances mucosal and systemic humoral responses through help provided by Th1-type cytokines and select Th2-type cytokines, with CCL5 promoting Th1 and Th2 responses [10]. The results in the present study suggest that CCL5 is required for optimal Th1 cellular responses against and clearance of Chlamydia. These results corroborate our previous findings that CCR5-dependent mucosal immune responses are required for the efficient clearance of genital chlamydial infection, while functional CCR5 expression reduces infertility as a pathologic consequence of Th1-mediated inflammation associated with infection [22].
###end p 34
###begin p 35
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ccl5 </italic>
###xml 169 174 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ccl5 </italic>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 585 594 585 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ccr5&#916;</italic>
###xml 789 799 785 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 1114 1123 1110 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ccr5&#916;</italic>
###xml 1130 1144 1122 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In1.1T/C ccl5 </italic>
###xml 1204 1213 1196 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 450 478 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 480 483 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The ccl5 gene has a number of physiologically relevant single nucleotide polymorphisms that affect its function and expression. In particular, the In1.1T/C haplotype of ccl5 is highly prevalent (~37%) in African Americans, than compared to Americans of European origin (~0.3%), and results in significantly lower CCL5 expression [48]. This has been attributed to some of the health disparities between these ethic/racial groups; specifically, higher human immunodeficiency virus (HIV) susceptibility and faster progression to acquired immune deficiency syndrome (AIDS). Similar to the ccr5Delta32 polymorphism, the data in this study and others suggest diminished CCL5-CCR5 interactions could yield reduced fallopian tube scarring, but could also result in higher transmission/shedding of Chlamydia via decreased chlamydial clearance. It is plausible that a host with a modestly compromised innate immune system would on one hand - avoid infertility by mounting reduced Th1 responses and on the other - be unable to optimally clear a chlamydial infection. This would provide an evolutionary rationale for not only ccr5Delta32 and In1.1T/C ccl5 polymorphisms, but also the propagation and transmission of Chlamydia. No doubt, demonstration of this postulate will require additional and extensive studies.
###end p 35
###begin title 36
Conclusion
###end title 36
###begin p 37
###xml 270 279 270 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 391 400 391 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 463 476 463 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muriduram </italic>
Understanding the cellular and molecular mechanisms that CCL5 uses to modulate mucosal immunity is essential to better understanding the pathogenesis of chlamydial infection. We tested the hypothesis that CCL5 is essential for inducing adaptive mucosal immunity against Chlamydia. We conclude that CCL5 supports the induction of Th1 cytokine and IgG2a Ab as well as IgA Ab responses against Chlamydia. The suppression of CCL5 correlated with delayed clearance of C. muriduram infection, which suggests chlamydial immunity is mediated by Th1 immune responses driven in part by CCL5.
###end p 37
###begin title 38
Methods
###end title 38
###begin title 39
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
Chlamydia stocks
###end title 39
###begin p 40
###xml 14 34 14 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia muridarum </italic>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 14 33 <span type="species:ncbi:83560">Chlamydia muridarum</span>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
Stocks of the Chlamydia muridarum (trachomatis agent for mice) were prepared by propagating elementary bodies (EBs) in McCoy cells and used to infect mice as previously described [49]. The stocks were tittered by infecting McCoy cells with varying dilutions of EBs. The infectious titer was expressed as inclusion-forming units per milliliter (IFU/ml).
###end p 40
###begin title 41
Anti-CCL5 antibody production
###end title 41
###begin p 42
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 193 195 193 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 574 576 573 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
###xml 69 76 <span type="species:ncbi:9986">rabbits</span>
###xml 97 103 <span type="species:ncbi:10090">murine</span>
###xml 215 221 <span type="species:ncbi:9986">rabbit</span>
###xml 688 694 <span type="species:ncbi:9986">rabbit</span>
Murine anti-CCL5 was produced as previously described [34]. Briefly, rabbits were immunized with murine CCL5 (Pepro-Tech) and the hyper immune CCL5 antisera obtained was yielded titers of ~1:106 such that 10 mul of rabbit CCL5 antiserum neutralized 20 ng of CCL5. This antiserum was titrated by direct ELISA, and no cross-reactivity was detected when tested against other CCR5 ligands, chemokines and cytokines. Subsequently, antisera were heat-inactivated and purified using an IgG isotype-specific protein A column (Pierce). Anti-CCL5 Ab titers were adjusted to 1 : 4 x 105 (i.e., 50x dilution) in PBS (Ab solution) for CCL5 blocking experiments. Similarly prepared normal or preimmune rabbit serum was used to generate the control Ab solution.
###end p 42
###begin title 43
Animal infection, Ab treatment, and analysis of disease course
###end title 43
###begin p 44
###xml 732 734 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 784 786 783 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 793 806 792 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 1247 1249 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1260 1270 1258 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 1447 1457 1445 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
###xml 1558 1560 1556 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 607 611 <span type="species:ncbi:10090">mice</span>
###xml 793 805 <span type="species:ncbi:83560">C. muridarum</span>
###xml 865 869 <span type="species:ncbi:10090">mice</span>
###xml 917 921 <span type="species:ncbi:10090">Mice</span>
###xml 926 930 <span type="species:ncbi:10090">mice</span>
###xml 1196 1200 <span type="species:ncbi:10090">mice</span>
Female BALB/c mice, ages 6 to 8 weeks, were purchased from Jackson Laboratory and used to establish a colony at the Morehouse School of Medicine animal facility. The animals were housed and maintained in isolator cages under specific-pathogen-free housing conditions. The guidelines proposed by the Committee for the Care of Laboratory Animal Resources Commission of Life Sciences-National Research Council were followed to minimize animal pain and distress. These studies were approved by the Morehouse School of Medicine Institutional Animal Care and Use Committee (IACUC). Seven days prior to infection, mice received 2.5 mg of medroxy-progesterone acetate (Depo-Provera; The Upjohn Co.) by subcutaneous route in 100 mul of PBS [50]. Groups were intravaginally infected with 5 x 104 IFU of C. muridarum under phenobarbital anesthesia, whereas uninfected control mice received only phosphate buffered saline (PBS). Mice (15 mice per group) received 100 mul of either control or anti-CCL5 Abs by intraperitoneal injection, 24 hrs before chlamydial infection and every 72 hrs thereafter. The extent of unresolved chlamydial infection was monitored by taking cervico-vaginal swabs from individual mice every week until 42 days after the challenge [22]. Briefly,Chlamydia present in swabs were detected by infecting McCoy cells vaginal/swab rinses and staining infected monolayer with fluorescein isothiocyanate (FITC)-labeled, genus-specific, anti-Chlamydia Abs (Kallestad Diagnostics) to verify inclusion bodies (> 10 IFUs/ml) by direct immuno-fluorescence [49].
###end p 44
###begin title 45
Sample, tissue, and cell collection
###end title 45
###begin p 46
###xml 314 316 313 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 870 872 863 865 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 917 921 910 912 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 900 905 <span type="species:ncbi:10090">Mouse</span>
###xml 1334 1338 <span type="species:ncbi:9913">calf</span>
Vaginal cavities were rinsed three times with 50 mul of PBS to obtain mucosal secretions. Blood collected by retro-orbital bleeding and serum was separated following centrifugation. Serum and mucosal secretions were collected on 0, 7, 14, and 42 days post challenge and analyzed by ELISA. Following sacrifice by CO2 inhalation, spleen, ILN, fallopian tube(s), uterus, and cervix tissues were aseptically removed and single-cell suspensions were prepared by passing tissues through a sterile wire screen to quantify mRNA expression and T helper responses. Reproductive tract tissues were further disrupted to generate single cell suspensions by stirring in collagenase type IV (Sigma) in RPMI 1640 (collagenase solution) at 37degreesC for 30 min. Lymphocytes were further purified using a discontinuous Percoll (Pharmacia) gradient, collected at the 40/75% interface. CD4+ T cells were enriched using Mouse CD4 Cellect(R) plus columns according to manufacturer's protocol (Biotex Laboratories). Cell suspensions were washed twice in RPMI 1640 and lymphocytes were maintained in medium supplemented with 10 ml/L of nonessential amino acids (Mediatech), 1 mM sodium pyruvate (Sigma), 10 mM HEPES (Mediatech), 100 U/ml penicillin, 100 mug/ml streptomycin, 40 mug/ml gentamycin (Elkins-Sinn), 50 muM mercaptoethanol (Sigma), and 10% fetal calf serum (FCS) (Atlanta Biologicals).
###end p 46
###begin title 47
Chlamydia-specific T helper cell responses
###end title 47
###begin p 48
###xml 12 14 12 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 58 60 58 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 76 78 76 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 221 234 216 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 285 286 274 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 556 558 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 221 233 <span type="species:ncbi:83560">C. muridarum</span>
Purified CD4+ T cells were cultured at a density of 5 x 106 cells/ml with 106 cells/ml gamma-irradiated (3,000 rads) naive splenic feeder cells in complete medium in the presence or absence of 10 mug/ml of UV-inactivated C. muridarum inclusion bodies (IBs) as Ag at 37degreesC in 5% CO2. After 3 days of culture, cells were pulsed with BrdU labeling solution and incorporation was detected by ELISA (Roche Molecular Biochemical). Similarly, cell culture supernatants were collected 3 days after culture and assayed for cytokine secretion by Luminex assay [34].
###end p 48
###begin title 49
Anti-Chlamydia Ab detection in serum and vaginal washes
###end title 49
###begin p 50
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia</italic>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 283 296 281 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 1123 1124 1108 1109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1125 1127 1110 1112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 283 295 <span type="species:ncbi:83560">C. muridarum</span>
Chlamydia-specific serum IgG subclass antibodies and vaginal wash IgA levels were quantified 6 weeks after challenge by ELISA [10]. Briefly, 96-well Falcon ELISA plates (Fisher Scientific) were coated with 100 mul of anti-IgG or IgA Ab (BD-PharMingen) or 10 mug/ml of UV-inactivated C. muridarum IBs in PBS O/N at 4degreesC and blocked with 10% FCS in PBS for 2 hrs at RT. IgM, IgG subclasses or IgA standards, and experimental samples were serially added after diluted with PBS. After O/N incubation at 4degreesC and three washes using PBS containing 0.05% Tween 20 (PBS-T), Ag-specific titers of IgM, IgG, IgA, or IgG subclass Abs were determined following the addition of biotinylated detection Abs (BD-PharMingen). After incubation and wash steps, anti-biotin HRP Ab (Vector Laboratories Inc., Burlingame, CA) in PBS-T was added to detection wells and incubated for 1 hr at RT. Following incubation, all plates were washed 6 times and the color reaction was developed by adding 100 mul of 1.1 mM 2,2'-azino-bis(3)-ethylbenzthiazoline-6-sulfonic acid (Sigma) in 0.1 M citrate-phosphate buffer (pH 4.2) containing 0.01% H2O2 (ABTS solution).
###end p 50
###begin title 51
Cytokine detection
###end title 51
###begin p 52
###xml 123 128 <span type="species:ncbi:10090">mouse</span>
###xml 923 928 <span type="species:ncbi:10090">mouse</span>
The presence of the following T helper cell-derived cytokines in culture supernatants was determined by Beadlytetrade mark mouse multi-cytokine detection system kit (BioRad): interleukin (IL)-2, IL-4, IL-6, IL-10, granulocyte monocyte cell stimulating factor (GM-CSF), and interferon (IFN)-gamma. Filter-bottom ELISA plates (BioRad) were rinsed with 100 mul of Bioplex assay buffer and the buffer was removed using a Milliporetrade mark multiscreen separation vacuum manifold system set at 5 mm Hg. Analyte beads in assay buffer were added into wells, followed by 50 mul of serum or standard solution and incubated for 30 mins at RT with continuous shaking (at setting #3) using a Lab-Linetrade mark Instrument Titer Plate Shaker (Melrose, IL). The filter-bottom plates were washed as before and the buffer was removed using a Milliporetrade mark multiscreen separation vacuum manifold system. Subsequently, 50 mul of anti-mouse IL-2, IL-4, IL-6, IL-10, GM-CSF, or IFN-gamma Ab-biotin reporter solution was added in each well and the plates were incubated with continuous shaking for 30 mins followed by centrifugation and washing. Next, 50 mul of streptavidin-phycoerytherin (PE) solution was added and the plates were incubated with continuous shaking for 10 mins at RT. 125 mul of Bio-plex assay buffer was added and Beadlytetrade mark readings were measured using a Luminextrade mark System and calculated using Bio-plextrade mark software (Bio-Rad). The cytokine Beadlytetrade mark assays were capable of detecting > 5 pg/ml for each analyte.
###end p 52
###begin title 53
RNA isolation and gene expression analysis
###end title 53
###begin p 54
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
Total RNA from the spleen, ILNs, fallopian tube, uterus, and cervix leukocytes was isolated from mouse treated with anti-CCL5 or control Ab using Tri-reagenttrade mark (Molecular Research Center, Cincinnati, OH). Potential genomic DNA contamination was removed from these samples by treatment with RNase-free DNase (Invitrogen) for 15 mins at 37degreesC. RNA was then precipitated and re-suspended in RNA secure (Ambion). cDNA was generated by reverse transcribing approximately 1.5 mug of total RNA using Taqmantrade mark reverse transcription reagent (Applied Biosystems).
###end p 54
###begin p 55
###xml 1329 1333 1312 1314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 1090 1096 <span type="species:ncbi:10090">murine</span>
Mouse mRNA sequences of CCL5, CCR5, IFN-gamma, and 18S rRNA were obtained from the NIH-NCBI gene bank database accession numbers NM03653, D83648, K00083, and X00686.1, respectively. These sequences were then used to design primers for real-time polymerase chain reaction (RT-PCR) analysis, which generated amplicons of 97, 100, 98, and 149 base pairs size, respectively, for CCL5 (sense-TCG TGT TTG TCA CTC GAA GG and antisense- GCT GAT GGC CTG ATT GTC TT), CCR5 (sense- CGA AAA CAC ATG GTC AAA CG and antisense- GGG AAG CGT ATA CAG GGT CA, IFN-gamma (sense- ACT GGC AAA AGG ATG GTG AC and antisense- GTT CTC CTG TGG ATC GGG TA), and 18S rRNA (sense-GTA ACC CGT TGA ACC CAA TT and antisense- CAA TCC AAT CGG TAG TAG CG). Primers were designed using the primer 3 software program from Whitehead Institute at the Massachusetts Institute of Technology (MIT). Thermodynamic analysis of primers was conducted using the following computer programs: Primer Premiertrade mark (Integrated DNA Technologies) and MIT Primer III (Boston, MA). The resulting primer sets were compared against the entire murine genome using the National Center for Biotechnology Information (NCBI) to confirm specificity and ensure that the primers flanked mRNA splicing regions. cDNA was generated as before and amplified with specific cDNA primers using SYBR(R) Green PCR master mix reagents (Applied Biosystems). The copy number (> 10) of mRNA relative to 18S rRNA copies was evaluated by RT-PCR analysis using the BioRad Icycler and software (Hercules, CA).
###end p 55
###begin title 56
Statistics
###end title 56
###begin p 57
###xml 104 105 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 139 140 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 191 193 189 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Data were expressed as the mean +/- standard error of mean (SEM), compared using a two-tailed student's t-test or an unpaired Mann Whitney U-test, and considered statistically significant if p < 0.01. When cytokine levels were below detection (BD) limit, they were recorded as one-half the lower detection limit (e.g., 5 pg/ml for IL-10) for statistical analysis.
###end p 57
###begin title 58
Abbreviations
###end title 58
###begin p 59
###xml 270 274 <span type="species:ncbi:9913">calf</span>
###xml 369 372 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 374 402 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 409 414 <span type="species:ncbi:9796">horse</span>
###xml 415 421 <span type="species:ncbi:3726">radish</span>
Ab: antibody; ABTS: 2,2'-azino-bis(3)-ethylbenzthiazoline-6-sulfonic acid; Ag: antigen; AIDS: acquired immunodeficiency syndrome; BD: below detection; BrdU: bromodeoxyuridine; DAB: diaminobenzedine tetrahydrochloride; DC: dendritic cell; EB: elementary body; FCS: fetal calf serum; FITC: fluorescein isothiocyanate; GMCSF: granulocyte monocyte cell stimulating factor; HIV: human immunodeficiency virus; HRP: horse radish peroxidase; IB: inclusion body; IFN: interferon; IFU/ml: inclusion-forming units per milliliter; Ig: immunoglobulin; IL: interleukin; ILN: iliac lymph node; MHC: major histocompatibility complex; MIT: Massachusetts Institute of Technology; NCBI: National Center for Biotechnology Information; OD: optical density; O/N: over night; PBS: phosphate buffered saline; PBS-T: PBS Tween; PE: phycoerytherin; RPMI: Roswell Park Memorial Institute; RT: room temperature; RT-PCR: real-time polymerase chain reaction; SEM: Standard Error of Mean; TBS: tris-buffered saline; Th1: T helper type 1; TNF: tumor necrosis factor; UV: ultra violet.
###end p 59
###begin title 60
Authors' contributions
###end title 60
###begin p 61
###xml 103 116 103 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muriduram </italic>
###xml 293 306 293 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muriduram </italic>
SKS and UPS carried-out all animal studies. SKS quantified serum and vaginal wash Ab levels as well as C. muriduram shedding. UPS isolated and measured mRNA levels as well as T cell cytokine secretion. DDT provided CCL5 and anti-CCL5 Ab as well as helped to draft the manuscript. JUI provided C. muriduram EBs and determined the corresponding titer. JWL as well as JUI conceived the study, participated in its design with all authors, coordinated and helped to draft the manuscript with the assistance of all authors. All authors read and approved the final manuscript. The authors declare that they have no competing interests.
###end p 61
###begin title 62
Acknowledgements
###end title 62
###begin p 63
This work was supported in part by National Institute of Health grants RR03034, GM08248, MD000525, AI41231 and AI57808 and the Smith & Lucille Gibson Endowment in Medicine. This research was also supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. The content of this manuscript benefited from many fruitful conversations with colleagues at Morehouse School of Medicine, Centers for Disease Control & Prevention, and University of Louisville as well as editing by Andrew Marsh.
###end p 63
###begin article-title 64
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
Chlamydia vaccines: strategies and status
###end article-title 64
###begin article-title 65
###xml 12 18 <span type="species:ncbi:10090">murine</span>
Immunity to murine chlamydial genital infection
###end article-title 65
###begin article-title 66
###xml 20 41 20 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis</italic>
###xml 20 41 <span type="species:ncbi:813">Chlamydia trachomatis</span>
T cell responses to Chlamydia trachomatis
###end article-title 66
###begin article-title 67
###xml 108 129 108 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis</italic>
###xml 66 70 <span type="species:ncbi:10090">mice</span>
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
###xml 108 129 <span type="species:ncbi:813">Chlamydia trachomatis</span>
Local Th1-like responses are induced by intravaginal infection of mice with the mouse pneumonitis biovar of Chlamydia trachomatis
###end article-title 67
###begin article-title 68
###xml 43 48 <span type="species:ncbi:9606">human</span>
Immune control of Chlamydial growth in the human epithelial cell line RT4 involves multiple mechanisms that include nitric oxide induction, tryptophan catabolism and iron deprivation
###end article-title 68
###begin article-title 69
###xml 63 85 63 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis </italic>
###xml 63 84 <span type="species:ncbi:813">Chlamydia trachomatis</span>
Protection against ascending infection of the genital tract by Chlamydia trachomatis is associated with recruitment of major histocompatibility complex class II antigen-presenting cells into uterine tissue
###end article-title 69
###begin article-title 70
###xml 118 140 118 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis </italic>
###xml 118 139 <span type="species:ncbi:813">Chlamydia trachomatis</span>
Differential regulation of CD4 lymphocyte recruitment between the upper and lower regions of the genital tract during Chlamydia trachomatis infection
###end article-title 70
###begin article-title 71
###xml 54 75 54 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis</italic>
###xml 54 75 <span type="species:ncbi:813">Chlamydia trachomatis</span>
Fc receptor regulation of protective immunity against Chlamydia trachomatis
###end article-title 71
###begin article-title 72
Lymphotactin acts as an innate mucosal adjuvant
###end article-title 72
###begin article-title 73
RANTES potentiates antigen-specific mucosal immune responses
###end article-title 73
###begin article-title 74
MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity
###end article-title 74
###begin article-title 75
Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses
###end article-title 75
###begin article-title 76
Chemokines as regulators of T cell differentiation
###end article-title 76
###begin article-title 77
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse strain-dependent chemokine regulation of the genital tract T helper cell type 1 immune response
###end article-title 77
###begin article-title 78
Synthesis of the CC-chemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response
###end article-title 78
###begin article-title 79
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s
###end article-title 79
###begin article-title 80
###xml 53 58 <span type="species:ncbi:9606">human</span>
Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells
###end article-title 80
###begin article-title 81
RANTES: a versatile and controversial chemokine
###end article-title 81
###begin article-title 82
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Impaired T cell function in RANTES-deficient mice
###end article-title 82
###begin article-title 83
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression
###end article-title 83
###begin article-title 84
###xml 60 63 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study
###end article-title 84
###begin article-title 85
###xml 63 85 63 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis </italic>
###xml 63 84 <span type="species:ncbi:813">Chlamydia trachomatis</span>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 141 146 <span type="species:ncbi:9606">women</span>
Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion
###end article-title 85
###begin article-title 86
Chemokine and chemokine receptor dynamics during genital chlamydial infection
###end article-title 86
###begin article-title 87
###xml 12 34 12 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis </italic>
###xml 12 33 <span type="species:ncbi:813">Chlamydia trachomatis</span>
Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways
###end article-title 87
###begin article-title 88
###xml 102 124 102 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis </italic>
###xml 102 123 <span type="species:ncbi:813">Chlamydia trachomatis</span>
Chemokine expression patterns differ within anatomically distinct regions of the genital tract during Chlamydia trachomatis infection
###end article-title 88
###begin article-title 89
###xml 20 24 <span type="species:ncbi:10090">mice</span>
###xml 121 127 <span type="species:ncbi:9606">humans</span>
Studies in knockout mice reveal that anti-chlamydial protection requires TH1 cells producing IFN-gamma: is this true for humans?
###end article-title 89
###begin article-title 90
###xml 20 22 20 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 113 133 113 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia muridarum </italic>
###xml 113 132 <span type="species:ncbi:83560">Chlamydia muridarum</span>
Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection
###end article-title 90
###begin article-title 91
###xml 109 124 <span type="species:ncbi:10090">transgenic mice</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele
###end article-title 91
###begin article-title 92
###xml 67 88 67 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis</italic>
###xml 60 66 <span type="species:ncbi:10090">murine</span>
###xml 67 88 <span type="species:ncbi:813">Chlamydia trachomatis</span>
Humoral and cellular immunity in secondary infection due to murine Chlamydia trachomatis
###end article-title 92
###begin article-title 93
###xml 29 51 29 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis </italic>
###xml 29 50 <span type="species:ncbi:813">Chlamydia trachomatis</span>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response
###end article-title 93
###begin article-title 94
Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES
###end article-title 94
###begin article-title 95
###xml 85 90 <span type="species:ncbi:9606">human</span>
Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils
###end article-title 95
###begin article-title 96
Chemokines, inflammation and the immune system
###end article-title 96
###begin article-title 97
CCL5 modulates pneumococcal immunity and carriage
###end article-title 97
###begin article-title 98
###xml 54 75 54 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis</italic>
###xml 54 75 <span type="species:ncbi:813">Chlamydia trachomatis</span>
Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine
###end article-title 98
###begin article-title 99
###xml 12 18 <span type="species:ncbi:10090">murine</span>
Recombinant murine IL-5 induces high rate IgA synthesis in cycling IgA-positive Peyer's patch B cells
###end article-title 99
###begin article-title 100
###xml 32 37 <span type="species:ncbi:9606">Human</span>
###xml 42 48 <span type="species:ncbi:10090">murine</span>
Interleukins and IgA synthesis. Human and murine interleukin-6 induce high rate IgA secretion in IgA-committed B cells
###end article-title 100
###begin article-title 101
Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella
###end article-title 101
###begin article-title 102
###xml 46 56 46 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia </italic>
Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine
###end article-title 102
###begin article-title 103
Induction of anti-chlamydial mucosal immunity by transcutaneous immunization is enhanced by topical application of GM-CSF
###end article-title 103
###begin article-title 104
Viral macrophage-inflammatory protein-II: a viral chemokine that differentially affects adaptive mucosal immunity compared with its mammalian counterparts
###end article-title 104
###begin article-title 105
###xml 29 42 29 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. muridarum </italic>
###xml 29 41 <span type="species:ncbi:83560">C. muridarum</span>
Intranasal immunization with C. muridarum major outer membrane protein (MOMP) and cholera toxin elicits local production of neutralising IgA in the prostate
###end article-title 105
###begin article-title 106
###xml 90 110 90 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia muridarum </italic>
###xml 90 109 <span type="species:ncbi:83560">Chlamydia muridarum</span>
Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection
###end article-title 106
###begin article-title 107
###xml 22 44 22 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis </italic>
###xml 111 132 111 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Borrelia burgdorferi </italic>
###xml 22 43 <span type="species:ncbi:813">Chlamydia trachomatis</span>
###xml 111 131 <span type="species:ncbi:139">Borrelia burgdorferi</span>
Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge
###end article-title 107
###begin article-title 108
###xml 116 138 116 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia trachomatis </italic>
###xml 100 106 <span type="species:ncbi:10090">murine</span>
###xml 116 137 <span type="species:ncbi:813">Chlamydia trachomatis</span>
Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection
###end article-title 108
###begin article-title 109
###xml 47 49 47 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 64 71 64 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo
###end article-title 109
###begin article-title 110
Differential expression and cross-regulatory function of RANTES during mycobacterial (type 1) and schistosomal (type 2) antigen-elicited granulomatous inflammation
###end article-title 110
###begin article-title 111
###xml 24 27 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Modulating influence on HIV/AIDS by interacting RANTES gene variants
###end article-title 111
###begin article-title 112
###xml 63 67 <span type="species:ncbi:10090">mice</span>
Resolution of chlamydial genital infection in B-cell-deficient mice and immunity to reinfection
###end article-title 112
###begin article-title 113
Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens
###end article-title 113

